nisevokitug
Term · Oncology and biomedicine · MLC-T-ONC-015515
A monoclonal antibody directed against human transforming growth factor beta (TGF-beta), with potential antineoplastic activity. Upon administration, nisevokitug targets and binds to TGF-beta, thereby preventing the activation of TGF-beta-mediated signaling pathways. TGF-beta, a pro-inflammatory mediator that is mutated and/or overexpressed in a number of cancer cell types, is involved in cancer cell proliferation and migration, and tumor progression.
| Identifier | MLC-T-ONC-015515 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | anti-TGF-beta monoclonal antibody NIS793 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-015515",
"term": "nisevokitug",
"field": "Oncology and biomedicine",
"definition": "A monoclonal antibody directed against human transforming growth factor beta (TGF-beta), with potential antineoplastic activity. Upon administration, nisevokitug targets and binds to TGF-beta, thereby preventing the activation of TGF-beta-mediated signaling pathways. TGF-beta, a pro-inflammatory mediator that is mutated and/or overexpressed in a number of cancer cell types, is involved in cancer cell proliferation and migration, and tumor progression.",
"synonyms": [
"anti-TGF-beta monoclonal antibody NIS793"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/nisevokitug/"
}
Record 11,851 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.